Chronic cavitary pulmonary aspergillosis in a teriflunomide-treated multiple sclerosis patient.
(2024) Clinical Neurology and Neurosurgery — Vol. 236, p. 108125 [1-2] (2024)
Files
LondonFClinNeurolNeurosurg2024.pdf
Open Access - Adobe PDF
- 1.26 MB
Details
- Authors
- Abstract
- Teriflunomide is a once-daily oral therapy approved for the treatment of relapsing forms of multiple sclerosis. Teriflunomide has been shown to reduce relapse rate and disability progression [1]. Its efficacy presumably results from of a selective and reversible inhibition of dihydro-orotate dehydrogenase (DHODH), a mitochondrial enzyme essential for de novo pyrimidine synthesis, and inducing a reduction of activated T and B cells without compromising mechanisms of adaptive immunity [2]. Although long-term risk of lymphopenia and infections is low in teriflunomide treated patients, monitoring lymphocyte counts is required [3]. We herein describe the case of a 55-year-old male patient with MS who developed pulmonary aspergilloma while receiving teriflunomide treatment.
- Affiliations
Citations
London, F., Stanciu-Pop, C., & Mulquin, N. (2024). Chronic cavitary pulmonary aspergillosis in a teriflunomide-treated multiple sclerosis patient. Clinical Neurology and Neurosurgery, 236, 108125 [1-2]. https://doi.org/10.1016/j.clineuro.2024.108125 (Original work published 2024)